Stimgenics

Stimgenics is the American startup which developed technology of stimulation of a spinal cord, so-called differential targeted multiplex neurostimulation (DTM). The private company is located in Bloomington, the State of Illinois.

History

2020: Sale to the company

At the beginning of January, 2020 Medtronic announced acquisition of the Stimgenics company which developed a type of an impulse for stimulation of a spinal cord (SCS), known as Differential Target Multiplexed SCS (DTM). The company is going to use technology of a startup in the implanted Intellis neurostimulator intended for treatment of chronic pain. Financial terms of transaction are not disclosed.

The Stimgenics mechanism differs from normal technologies of neurostimulation in the fact that allows to modulate activity of both neurons, and glial cages. In the press release Medtronic noted that the role of glial cages in nervous system which quantity by 12 times exceeds the number of neurons in a spinal cord was underestimated. But now researchers consider that the glia can play more significant role in development of chronic pain, than it was supposed earlier. Glial cages are not considered only as "glue" in a brain and a spinal cord any more: they play an important role in the course of transfer of a nervous signal and development of different pathological statuses, including chronic pain.

Medtronic announced Stimgenics acquisition

The Medtronic company conducts the randomized controlled study (RCS) with 250 to compare efficiency of a neurostimulator of Intellis to the standard mechanism and to Stimgenics technology. Medtronic is going to provide three-months results at a meeting of North American society of neuromodulation (NANS) at the end of January, 2020 and also to show the latest version of a neurostimulator of a spinal cord. In general the research of new technology will last 12 months.

The Impulse of DTM was studied on models of animals and showed statistically significant reduction of a pain syndrome in comparison with isolated low - or vysokochastototny stimulation. Besides, preclinical researches in which the genome of animals with the injured nerve was studied show that the pulse shape of DTM has a greater influence on neuro and glial interaction, than other frequencies.

The researches Stimgenics began with works on animals more than ten years ago. Our preclinical data showed that modulation of both neurons, and glial cages can normalize a status of a glia and change its interaction with active neurons. Thereby similar neurostimulation normalizes biological processes and destroys a cascade of pathological reactions at hronichseky pains — Ricardo Vallejo, the cofounder and the head of researches in Millennium Pain Center in Bloomington explained in the statement of Medtronic, the State of Illinois and also the founder and the leading researcher of Stimgenics, LLC.[1]

The preclinical researches Stimgenics on the neyronalno-glial mechanism of action were sounded and well met within the different scientific medical actions.

Medtronic aims to provide clinically checked treatment methods for millions of patients having chronic pain around the world — Marshall Stanton, the doctor of medical sciences, the head of department on treatment of chronic pain (Pain Therapies), entering into group of recovery therapy (Restorative Therapies Group) of Medtronic company said. — We consider that therapy of DTM will promote more effective treatment of chronic pain that is confirmed by clinical data and preclinical researches of the neyronalno-glial mechanism of action. This fascinating patented pulse shape will be available on the Intellis platform, and we with impatience expect to see results of randomized controlled study at the NANS conference.

It is expected that this transaction will be neutral in relation to earning per share in 2020 financial year and will correspond to long-term financial performance of Medtronic company on acquisitions.

Notes